Cyclic Vomiting Syndrome
Conditions
Brief summary
The main purpose of this study is the comparison of frequency of vomiting episodes (number of episodes per year) observed during the year after the begin of Q10 coenzyme treatment to frequency observed during the year before the begin of this treatment in children with cyclic vomiting syndrome. Secondary purposes are the evaluation of life quality of parents and children, of treatment safety and its economic cost compared to other recommended treatments.
Interventions
DRUGQ10 Coenzyme
Sponsors
Central Hospital, Nancy, France
Study design
Observational model
CASE_CROSSOVER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 17 Years
Healthy volunteers
No
Inclusion criteria
* Cyclic vomiting syndrome as defined by Rome IV criteria * Treated with Q10 coenzyme treatment for cyclic vomiting syndrome * Q10 coenzyme treatment started between January 2000 and July 2006
Exclusion criteria
\- Refusal of processing of personal data reported in patient medical files
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of vomiting episodes | from date of inclusion (start of Q10 coenzyme treatment) up to 1 year | measured by number of episodes per year |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Intensity of vomiting episodes | from 1 year before date of inclusion until date of inclusion (start of Q10 coenzyme treatment) | reported by the child and/or parents |
| Number of child hospitalizations | from 1 year before date of inclusion until date of inclusion (start of Q10 coenzyme treatment) | — |
| Cost of Q10 coenzyme treatment and other recommended treatments for cyclic vomiting syndrome | baseline | — |
Countries
France
Outcome results
None listed